| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| P Jenne. Pathophysiology and biochemistry of dyskinesia: clues for the development of non-dopaminergic treatments. Journal of neurology. vol 247 Suppl 2. 2000-09-14. PMID:10991665. |
however, there are no consistent changes in dopamine receptors which explain the occurrence of dyskinesia. |
2000-09-14 |
2023-08-12 |
Not clear |
| O Rasco. The pharmacological therapeutic management of levodopa-induced dyskinesias in patients with Parkinson's disease. Journal of neurology. vol 247 Suppl 2. 2000-09-14. PMID:10991666. |
once present, dyskinesias are only partially improved by lowering the daily dose of levodopa and co-administering a d2 dopamine agonist. |
2000-09-14 |
2023-08-12 |
Not clear |
| J M Van Kampen, A J Stoess. Effects of oligonucleotide antisense to dopamine D(1A) receptor messenger RNA in a rodent model of levodopa-induced dyskinesia. Neuroscience. vol 98. issue 1. 2000-08-24. PMID:10858612. |
effects of oligonucleotide antisense to dopamine d(1a) receptor messenger rna in a rodent model of levodopa-induced dyskinesia. |
2000-08-24 |
2023-08-12 |
rat |
| J M Van Kampen, A J Stoess. Effects of oligonucleotide antisense to dopamine D(1A) receptor messenger RNA in a rodent model of levodopa-induced dyskinesia. Neuroscience. vol 98. issue 1. 2000-08-24. PMID:10858612. |
the pathophysiology underlying these dyskinesias remains unclear, although, it has been suggested that heightened activity of dopamine d(1) receptor-bearing striatonigral neurons may play a key role. |
2000-08-24 |
2023-08-12 |
rat |
| J M Van Kampen, A J Stoess. Effects of oligonucleotide antisense to dopamine D(1A) receptor messenger RNA in a rodent model of levodopa-induced dyskinesia. Neuroscience. vol 98. issue 1. 2000-08-24. PMID:10858612. |
in these studies, we further clarify the role of the dopamine d(1a) receptor in this rodent model of levodopa-induced dyskinesias using an in vivo oligonucleotide antisense approach. |
2000-08-24 |
2023-08-12 |
rat |
| J M Van Kampen, A J Stoess. Effects of oligonucleotide antisense to dopamine D(1A) receptor messenger RNA in a rodent model of levodopa-induced dyskinesia. Neuroscience. vol 98. issue 1. 2000-08-24. PMID:10858612. |
thus, the dopamine d(1a) receptor appears to play a significant role in levodopa-induced dyskinesias and warrants further examination. |
2000-08-24 |
2023-08-12 |
rat |
| C S Lee, M A Cenci, M Schulzer, A Björklun. Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease. Brain : a journal of neurology. vol 123 ( Pt 7). 2000-08-07. PMID:10869049. |
we investigated the role of dopamine neurons in the manifestation of levodopa-induced dyskinesia in a rat model of parkinson's disease. |
2000-08-07 |
2023-08-12 |
rat |
| C S Lee, M A Cenci, M Schulzer, A Björklun. Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease. Brain : a journal of neurology. vol 123 ( Pt 7). 2000-08-07. PMID:10869049. |
we conclude that embryonic dopamine neuronal grafts may improve levodopa-induced dyskinesia by restoring altered activities of postsynaptic neurons, resulting not only from dopamine denervation, but also from levodopa therapy, provided that the density of striatal dopaminergic nerve terminals is restored above a 'threshold' level. |
2000-08-07 |
2023-08-12 |
rat |
| C G Charlton, B Crowel. Effects of dopamine metabolites on locomotor activities and on the binding of dopamine: relevance to the side effects of L-dopa. Life sciences. vol 66. issue 22. 2000-06-15. PMID:10834300. |
the dyskinesia develops over a period of exposure to l-dopa and is related to the dosage, therefore, the cause may involve inductive changes that produce toxic levels of metabolites, interfering with dopamine (da) neurotransmission. |
2000-06-15 |
2023-08-12 |
rat |
| T Kanda, M J Jackson, L A Smith, R K Pearce, J Nakamura, H Kase, Y Kuwana, P Jenne. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Experimental neurology. vol 162. issue 2. 2000-05-23. PMID:10739638. |
combined use of the adenosine a(2a) antagonist kw-6002 with l-dopa or with selective d1 or d2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in mptp-treated monkeys. |
2000-05-23 |
2023-08-12 |
monkey |
| P Damier, L Tremblay, J Féger, E C Hirsc. [Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)]. Revue neurologique. vol 156. issue 3. 2000-05-16. PMID:10740093. |
pulsatile activation of type d2 dopamine receptors is reported to be the principal factor in the triggering of dyskinesias and may well be involved in the priming phenomenon. |
2000-05-16 |
2023-08-12 |
monkey |
| S Fah. The spectrum of levodopa-induced dyskinesias. Annals of neurology. vol 47. issue 4 Suppl 1. 2000-04-21. PMID:10762127. |
most of the dyskinesias occur at the time of the highest brain concentration of levodopa and its product, dopamine--so-called peak-dose dyskinesias. |
2000-04-21 |
2023-08-12 |
Not clear |
| C R Gerfe. Dopamine-mediated gene regulation in models of Parkinson's disease. Annals of neurology. vol 47. issue 4 Suppl 1. 2000-04-21. PMID:10762131. |
the molecular and cellular mechanisms underlying the irreversibility of this supersensitive response with long-term dopamine agonist treatments may provide insights into dyskinesias that develop with long-term levodopa therapy in the treatment of pd. |
2000-04-21 |
2023-08-12 |
Not clear |
| J J Canales, A M Graybie. Patterns of gene expression and behavior induced by chronic dopamine treatments. Annals of neurology. vol 47. issue 4 Suppl 1. 2000-04-21. PMID:10762132. |
the induction of high-intensity motor stereotypies by dopamine d1- and d2-class receptor agonists, the sensitized behavioral responsiveness to psychostimulant drugs in normal animals, and the progressive sensitization of dyskinesias after intermittent treatment with dopamine agonists following dopamine depletion are all correlated with persistent changes in gene induction in the striatum. |
2000-04-21 |
2023-08-12 |
Not clear |
| F Calon, R Grondin, M Morissette, M Goulet, P J Blanchet, T Di Paolo, P J Bédar. Molecular basis of levodopa-induced dyskinesias. Annals of neurology. vol 47. issue 4 Suppl 1. 2000-04-21. PMID:10762134. |
biochemical analysis of the brains revealed several alterations in dopamine receptor-binding and messenger rna message following denervation and dopaminergic treatment, but none that clearly correlated with the presence of dyskinesias. |
2000-04-21 |
2023-08-12 |
monkey |
| F Calon, R Grondin, M Morissette, M Goulet, P J Blanchet, T Di Paolo, P J Bédar. Molecular basis of levodopa-induced dyskinesias. Annals of neurology. vol 47. issue 4 Suppl 1. 2000-04-21. PMID:10762134. |
we suggest that levodopa-induced dyskinesias represent a form of pathological learning, which results from deficient gating of glutamatergic inputs to the striatum by dopamine. |
2000-04-21 |
2023-08-12 |
monkey |
| J W Langston, M Quik, G Petzinger, M Jakowec, D A Di Mont. Investigating levodopa-induced dyskinesias in the parkinsonian primate. Annals of neurology. vol 47. issue 4 Suppl 1. 2000-04-21. PMID:10762135. |
it would appear that there is a different threshold of striatal dopamine depletion for parkinsonism and dyskinesias in the monkey. |
2000-04-21 |
2023-08-12 |
monkey |
| P Jenne. Factors influencing the onset and persistence of dyskinesia in MPTP-treated primates. Annals of neurology. vol 47. issue 4 Suppl 1. 2000-04-21. PMID:10762136. |
the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treated primate model of parkinson's disease provides a unique opportunity to study factors influencing the onset and persistence of dyskinesia induced by levodopa or dopamine agonist treatment. |
2000-04-21 |
2023-08-12 |
Not clear |
| P Jenne. Factors influencing the onset and persistence of dyskinesia in MPTP-treated primates. Annals of neurology. vol 47. issue 4 Suppl 1. 2000-04-21. PMID:10762136. |
short-acting pulsatile dopamine agonists are more likely to induce dyskinesia than drugs that have a long duration of effect and produce continuous receptor stimulation. |
2000-04-21 |
2023-08-12 |
Not clear |
| P Jenne. Factors influencing the onset and persistence of dyskinesia in MPTP-treated primates. Annals of neurology. vol 47. issue 4 Suppl 1. 2000-04-21. PMID:10762136. |
the induction of dyskinesia does not seem to be associated with any obvious change in the number or sensitivity of post-synaptic dopamine receptors, but rather to downstream events associated with the indirect and direct output pathways. |
2000-04-21 |
2023-08-12 |
Not clear |